„TRECID”: TNFα-assoziierte chronisch entzündliche Erkrankungen

Zusammenfassung

In der Pathogenese infektiöser und entzündlicher Erkrankungen nimmt das proinflammatorische Zytokin TNFα eine Schlüsselposition ein. Die Aufklärung seiner zentralen Rolle in der Pathogenese von rheumatoider Arthritis, Spondyloarthritiden, Uveitis, Psoriasis und bei chronisch entzündlichen Darmerkrankungen hat zur Entwicklung von gegen TNFα gerichteten Therapien geführt, bei denen eine Erkrankungs-modifizierende Wirksamkeit beobachtet wird, die über diejenige früherer Therapieoptionen hinausgehen kann.

Befunde über das Auftreten weiterer chronisch entzündlicher Autoimmunerkrankungen bei Patienten, die bereits an einer solchen Erkrankung leiden, haben zur Hypothese geführt, dass gemeinsame pathologische Prozesse dieser Zytokin-Dysregulation zugrunde liegen könnten. Entsprechend wurde der Begriff TRECID als Oberbegriff für TNFα-assoziierte chronisch entzündliche Erkrankungen entwickelt.

Ärzte verschiedener Fachdisziplinen haben aufgrund dieser Pathophysiologie in den letzten Jahren neue Therapieoptionen mit TNFα-Blockern in ihr Behandlungskonzept integriert. Das TRECID-Konzept kann daher als Modell für eine dynamische, Disziplin-übergreifende Zusammenarbeit auf gemeinsamer pathophysiologischer Basis gelten.

Summary

The pro-inflammatory cytokine TNF alpha (TNF) has a key position in the pathogenesis of various infectious and inflammatory diseases. Clarification of its pivotal role in the pathogenesis of rheumatoid arthritis, spondyloarthritis, uveitis, psoriasis and inflammatory bowel disease has resulted in the successful development of TNF- blocking therapies, which have disease-modifying properties that exceed the effects of conventional therapeutic options. For this reason data on the concurrence of several chronic inflammatory diseases have led to the hypothesis of common pathogenetic processes of cytokine dysregulation. The acronym TRECID describes this concept of „TNF RElated Chronic Inflammatory Diseases”. Physicians of different specialties have integrated new therapeutic options with TNF-blocking therapies into their strategies for the management of the affected patients. Thus the concept of TRECID can be regarded as a role model for a dynamic, interdisciplinary cooperation based on shared pathophysiological aspects.

TRECID - TNFα - rheumatoide Arthritis - Spondyloarthritis - chronisch entzündliche Darmerkrankungen - Psoriasis - Psoriasisarthritis - Uveitis

TRECID - TNFα - rheumatoid arthritis - ankyloarthritis - inflammatory bowel disease - psoriasis - psoriasis arthritis - uveitis

Literatur

• 1 Barrett J C, Hansoul S, Nicolae D L. et al . Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease.  Nat Genet. 2008;  40 955-962
• 2 Bjarnason I, Helgason K O, Geirsson A J. et al . Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis.  Gastroenterology. 2003;  125 1598-1605
• 3 Boehncke W H, Friedrich M, Kaltwasser J P. et al . Psoriasis-Arthritis – eine interdisziplinäre Herausforderung.  Dtsch Arztebl. 2006;  103 1455-1461
• 4 Boyman O, Hefti H P, Conrad C, Nickoloff B J, Suter M, Nestle F O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.  J Exp Med. 2004;  199 731-736
• 5 Braun J, Bollow M, Neure L. et al . Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.  Arthritis Rheum. 1995;  38 499-505
• 6 Breedveld F C, Weisman M H, Kavanaugh A F. et al . The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.  Arthritis Rheum. 2006;  54 26-37
• 7 Brito B E, O’Rourke L M, Pan Y, Anglin J, Planck S R, Rosenbaum J T. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis.  Invest Ophthalmol Vis Sci. 1999;  40 2583-2589
• 8 Brophy S, Pavy S, Lewis P. et al . Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors.  J Rheumatol. 2001;  28 2667-2673
• 9 Brophy S, Taylor G, Blake D, Calin A. The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis.  J Rheumatol. 2003;  30 2054-2058
• 10 Colombel J F, Rutgeerts P, Reinisch W. et al .SONIC: A randomized, double-blind, controled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. 16th United European Gastroenterology Week. Abstract OP001. Wien, Österreich; 20.10.2008
• 11 D’Haens G, Baert F, van Assche G. et al . Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial.  Lancet. 2008;  371 660-667
• 12 Danese S, Semeraro S, Papa A. et al . Extraintestinal manifestations in inflammatory bowel disease.  World J Gastroenterol. 2005;  11 7227-7236
• 13 Gottlieb A B, Evans R, Li S. et al . Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.  J Am Acad Dermatol. 2004;  51 534-542
• 14 Hampe J, Franke A, Rosenstiel P. et al . A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1.  Nat Genet. 2007;  39 207-211
• 15 Hanauer S B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.  Inflamm Bowel Dis. 2006;  12 Suppl 1 S3-9
• 16 Hyams J, Crandall W, Kugathasan S. et al . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children.  Gastroenterology. 2007;  132 863-873; quiz 1165–1166
• 17 Krüger K, Augustin M, Rauch C, Reich K. Prevalence and clinical manifestation of arthritis in a daily practice psoriasis population – a prospective observational epidemiological study in Germany.  Ann Rheum Dis. 2006;  65 531; Abs SAT0265
• 18 Lee F I, Bellary S V, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives.  Am J Gastroenterol. 1990;  85 962-963
• 19 Loftus Jr E V. Biologic therapy in Crohn’s disease: review of the evidence.  Rev Gastroenterol Disord. 2007;  7 Suppl 1 S3-S12
• 20 Luyten F P, Lories R J, Verschueren P, de Vlam K, Westhovens R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases.  Best Pract Res Clin Rheumatol. 2006;  20 829-848
• 21 Märker-Hermann E, Frauendorf E, Zeidler H, Sieper J. Pathogenese der ankylosierenden Spondylitis – Mechanismen der Krankheitsentstehung und Chronifizierung [Pathogenesis of ankylosing spondylitis-mechanisms of disease manifestation and chronicity].  Z Rheumatol. 2004;  63 187-192
• 22 Matsuo T, Koyama T, Morimoto N, Umezu H, Matsuo N. Retinal vasculitis as a complication of rheumatoid arthritis.  Ophthalmologica. 1990;  201 196-200
• 23 Mielants H, Veys E M, Cuvelier C, De Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences.  Baillieres Clin Rheumatol. 1996;  10 147-164
• 24 Mrowietz U, Elder J T, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients.  Arch Dermatol Res. 2006;  298 309-319
• 25 Murphy C C, Ayliffe W H, Booth A, Makanjuola D, Andrews P A, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.  Ophthalmology. 2004;  111 352-356
• 26 Nissinen R, Leirisalo-Repo M, Nieminen A M. et al . Immune activation in the small intestine in patients with rheumatoid arthritis.  Ann Rheum Dis. 2004;  63 1327-1330
• 27 Papp K A, Tyring S, Lahfa M. et al . A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.  Br J Dermatol. 2005;  152 1304-1312
• 28 Persson P G, Leijonmarck C E, Bernell O, Hellers G, Ahlbom A. Risk indicators for inflammatory bowel disease.  Int J Epidemiol. 1993;  22 268-272
• 29 Quinn M A, Conaghan P G, O’Connor P J. et al . Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 2005;  52 27-35
• 30 Rabinovich C E. Use of tumor necrosis factor inhibitors in uveitis.  Curr Opin Rheumatol. 2007;  19 482-486
• 31 Reich K, Hüffmeier U, König I R. et al . TNF polymorphisms in psoriasis: Association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele.  Arthritis Rheum. 2007;  56 2056-2064
• 32 Reich K, Nestle F O, Papp K. et al . Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.  Lancet. 2005;  366 1367-1374
• 33 Reveille J D, Arnett F C. Spondyloarthritis: update on pathogenesis and management.  Am J Med. 2005;  118 592-603
• 34 Rogler G, Brand K, Vogl D. et al . Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa.  Gastroenterology. 1998;  115 357-369
• 35 Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease.  Best Pract Res Clin Rheumatol. 2006;  20 451-471
• 36 Rutgeerts P. Modern therapy for inflammatory bowel disease.  Scand J Gastroenterol Suppl. 2003;  237 30-33
• 37 Rutgeerts P, Sandborn W J, Feagan B G. et al . Infliximab for induction and maintenance therapy for ulcerative colitis.  N Engl J Med. 2005;  353 2462-2476
• 38 Santos Lacomba M, Marcos Martin C, Gallardo Galera J M. et al . Aqueous Humor and Serum Tumor Necrosis Factor-alpha in Clinical Uveitis.  Ophthalmic Research. 2001;  33 251-255
• 39 Sartor R B. Importance of intestinal mucosal immunity and luminal bacterial cell wall polymers in the aetiology of inflammatory joint diseases.  Baillieres Clin Rheumatol. 1989;  3 223-245
• 40 Saurenmann R K, Levin A V, Rose J B. et al . Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.  Rheumatology (Oxford). 2006;  45 982-989
• 41 Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease.  Gut. 1998;  42 477-484
• 42 Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease.  Nat Rev Genet. 2005;  6 376-388
• 43 Scott D L, Kingsley G H. Tumor necrosis factor inhibitors for rheumatoid arthritis.  N Engl J Med. 2006;  355 704-712
• 44 Simmonds R E, Foxwell B M. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation.  Rheumatology (Oxford). 2008;  47 584-590
• 45 Suhler E B, Smith J R, Wertheim M S. et al . A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.  Arch Ophthalmol. 2005;  123 903-912
• 46 Taylor P C, Williams R O, Feldmann M. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases.  Curr Opin Biotechnol. 2004;  15 557-563
• 47 van der Heijde D, Klareskog L, Rodriguez-Valverde V. et al . Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.  Arthritis Rheum. 2006;  54 1063-1074
• 48 van Roon J A, Bijlsma J W, Lafeber F P. Diversity of regulatory T cells to control arthritis.  Best Pract Res Clin Rheumatol. 2006;  20 897-913
• 49 Villani A C, Lemire M, Fortin G. et al . Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility.  Nat Genet. 2009;  41 71-76
• 50 Watanabe T, Kitani A, Strober W. NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn’s disease.  Gut. 2005;  54 1515-1518
• 51 Williams J P, Meyers J A. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs.  Am J Manag Care. 2002;  8 S664-681; quiz S682–665
• 52 Zochling J, van der Heijde D, Burgos-Vargas R. et al . ASAS/EULAR recommendations for the management of ankylosing spondylitis.  Ann Rheum Dis. 2006;  65 442-452